Abstract
Background: Efficacy and safety data of COVID-19 vaccines among cancer populations have been limited; however, preliminary data from recent studies have emerged regarding their immunogenicity and safety in this population. In this review, we examined current peer-reviewed publications containing serological and safety data after COVID-19 vaccination of patients with cancer.
Methods: This analysis examined 21 studies with a total of 5012 patients with cancer, of which 2676 (53%) had haematological malignancies, 2309 (46%) had solid cancers and 739 were healthy controls. Serological responses by anti-SARS-CoV-2 spike protein S1/S2 immunoglobulin G antibody levels and post-vaccination patient questionnaires regarding vaccine-related side-effects after the first and second dose were collected and analysed.
Results: In general, a single dose of the COVID-19 vaccine yields weaker and heterogeneous serological responses in both patients with haematological and solid malignancies. On receiving a second dose, serological response rates indicate a substantial increase in seropositivity to the SARS-CoV-2 spike protein in all cancer cohorts, but antibody titres remain reduced in comparison with healthy controls. Furthermore, seroconversion in patients with haematological malignancies was significantly lower than that in patients with solid tumours. COVID-19 vaccines are safe and well-tolerated in patients with cancer based on current data of local and systemic effects.
Conclusion: Together, these data support the prioritisation of patients with cancer to receive their first and second doses to minimise the risk of COVID-19 infection and severe complications in this vulnerable population. Additional prophylactic measures must be considered for high-risk patients where current vaccination programs may not mount sufficient protection against SARS-CoV-2 infection.
Keywords: COVID-19; COVID-19 vaccines; Immunity; Neoplasms; SARS-CoV-2; Seroconversion.
【저자키워드】 COVID-19, SARS-CoV-2, Immunity, COVID-19 vaccines, Seroconversion, Neoplasms, 【초록키워드】 COVID-19 vaccine, vaccination, antibody, SARS-COV-2 infection, Cancer, Infection, haematological malignancies, Local, anti-SARS-CoV-2, Population, Spike protein, Seroconversion, COVID-19 vaccination, Immunoglobulin, systemic effects, response, Patient, serological, single dose, serological response, Antibody titre, Analysis, Safe, solid cancer, malignancy, solid malignancies, Tumours, prophylactic measure, Support, Patients with cancer, Side-effect, second dose, These data, S1/S2, cohorts, healthy controls, Preliminary data, heterogeneous, significantly lower, high-risk patient, risk of COVID-19, patient questionnaire, collected, examined, receiving, analysed, reduced, increase in, severe complication, receive, peer-reviewed, patients with haematological, the SARS-CoV-2, 【제목키워드】 COVID-19 vaccine, Patient, interim analysis,